Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome

Abstract

To assess the angiotensin II blocker effects on platelet (PL) aggregation in patients with arterial hypertension (AH) and metabolic syndrome (MS). In total, 35 patients received losartan for 16 weeks. Dynamics of plasma and PL lipid peroxidation, blood and PL antioxidant protection, and PL aggregation activity was investigated and analyzed using Student t-test. Losartan therapy improved peroxidation and PL aggregation parameters in patients with AH and MS.

Keywords

• arterial hypertension
• metabolic syndrome
• platelets
• losartan